Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System

Blood

Volumn 126, Issue 17, 2015, Pages 1996-2004

  Kuiper, Rowan ^a   Van Duin, Mark ^a   Van Vliet, Martin H ^a   Broijl, Annemiek ^a   Van Der Holt, Bronno ^b   Jarari, Laila El ^b   Van Beers, Erik H ^a   Mulligan, George ^c   Avet Loiseau, Hervé ^d   Gregory, Walter M ^e   Morgan, Gareth ^f   Goldschmidt, Hartmut ^g   Lokhorst, Henk M ^h   Sonneveld, Pieter ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d CHU RANGUEIL   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; DNA PACKAGING; DNA REPLICATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK POPULATION; INTERNATIONAL STAGING SYSTEM; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL TIME; CHROMOSOME ABERRATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; THEORETICAL MODEL;

AGED; BIOMARKERS, TUMOR; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84944910124     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-644039     Document Type: Article

References (40)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521-2526.
3. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996;93(24):13931-13936.
4. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569-4575.
5. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
6. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-2553.
7. Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406-2413.
8. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
9. Shaughnessy JD Jr, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118(13):3512-3524.
10. Decaux O, Lodé L, Magrangeas F, et al; Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29):4798-4805.
11. Hose D, Rème T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96(1):87-95.
12. Rème T, Hose D, Theillet C, Klein B. Modeling risk stratification in human cancer. Bioinformatics. 2013;29(9):1149-1157.
13. Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010;16(6):1856-1864.
14. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81(12):3382-3387.
15. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
16. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]. J Clin Oncol. 2005;23(15):3412-3420.
17. Chng WJ, Dispenzieri A, Chim CS, et al; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277.
18. Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t (4;14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150-1157.
19. Avet-Loiseau H, Durie BG, Cavo M, et al; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3):711-717.
20. Moreau P, Cavo M, Sonneveld P, et al. Combination of international scoring system 3, high lactate dehydrogenase, and t (4;14) and/or del (17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32(20):2173-2180.
21. Broyl A, Kuiper R, van Duin M, et al; Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624-627.
22. Morgan GJ, Davies FE, Gregory WM, et al. Longterm follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030-6038.
23. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-3188.
24. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-4173.
25. Ross FM, Ibrahim AH, Vilain-Holmes A, et al; UK Myeloma Forum. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia. 2005;19(9):1634-1642.
26. Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15):e56-e65.
27. Ross FM, Avet-Loiseau H, Ameye G, et al; European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272-1277.
28. Wuilleme S, Robillard N, Lodé L, et al; Intergroupe Francophone de Myélome. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275-278.
29. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-2955.
30. Cox DR, Oakes D. Analysis of Survival Data. Boca Raton, FL: Taylor & Francis; 1984.
31. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.
32. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
33. Ashburner M, Ball CA, Blake JA, et al; The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25-29.
34. Waheed S, Shaughnessy JD, van Rhee F, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. Cancer. 2011;117(5):1001-1009.
35. Meissner T, Seckinger A, Rème T, et al. Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine. Clin Cancer Res. 2011;17(23):7240-7247.
36. Hose D, Seckinger A, Jauch A, et al. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification. Srp Arh Celok Lek. 2011;139(Suppl 2):84-89.
37. Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001;97(8):2522-2523.
38. Gastinne T, Leleu X, Duhamel A, et al; Intergroupe Francophone du Myelome. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol. 2007;79(4):297-304.
39. Ludwig H, Sonneveld P, Davies F, et al. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829-844.
40. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reducedintensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109(8):3588-3594.